Literature DB >> 16462093

[Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].

Yoshiyuki Ohsugi1, Nobuyuki Tsuchimoto.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16462093     DOI: 10.1254/fpj.126.419

Source DB:  PubMed          Journal:  Nihon Yakurigaku Zasshi        ISSN: 0015-5691


× No keyword cloud information.
  2 in total

1.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

2.  Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody.

Authors:  Junya Kanda; Hiroshi Kawabata; Yuhei Yamaji; Tatsuo Ichinohe; Takayuki Ishikawa; Toshihiro Tamura; Yutaka Furukawa; Takeshi Kimura; Toru Kita; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.